CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.67 USD
+0.26 (10.79%)
Updated Jun 4, 2024 03:59 PM ET
After-Market: $2.70 +0.03 (1.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 1 - 20 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
High-Value Deal With Ewopharma Expanded to Include Pancreatic Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: COMFORT-PIII Psoriasis Data Published in the Journal of the European Academy of Dermatology and Venereology
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: FDA - Green Light Piclidenoson in Kids
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Valuation Rolls Forward - New Shares Registered
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Life is Precious - That?s What Can-Fite Thinks - Pancreatic Cancer Trial Set to Advance.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Reports 3rd Quarter Results: Spends $1.1M, $11M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Entry Into Rare Disease Field Could Enhance Piclidenoson?s Value; Reiterate Buy With an Adjusted PT of $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Reports 2nd Quarter Results: $9.6M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Namodenoson: Liver Cancer at ASCO Japan
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Going Pivotal - Two US-Based Psoriasis Trials Including Adolescents
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Extending Namodenoson to Pancreatic Cancer
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Preparing for a Pivotal Year; Reiterate Buy and $34 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY: Reports First Quarter - Provides Clinical Snapshot
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Raising to Buy from Neutral - $6.0 Price Target
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Neutral: Piclidenoson Gets the Go-Ahead to Start PIII Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Results With Compassionate Namodenoson Use in Decompensated Liver Cirrhosis Could Be Positive: Reit Buy and $34 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Piclidenoson and Namodenoson Continue With Strong Momentum Going Into 2023; Reit Buy With Post-ADS Adjusted Ratio $34 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V